Abstract 627P
Background
The prevalence of multiple primary neoplasms has been increasing over time, with primary colorectal cancer and primary prostate cancer being a common coexistence. Notably, a primary prostatic cancer was discovered in approximately one-sixth of men who underwent prostate cancer screening prior to rectal cancer excision. Due to a lack of knowledge about the racial disparity factor in this multiple primary malignancy, our study aims to assess the risk of developing primary prostate cancer between African Americans and Caucasians in patients with colorectal cancer.
Methods
We extracted the data from cancer registries in the Surveillance, Epidemiology, and End Results (SEER) database for patients with primary colorectal cancer from 2000-2020. This allowed us to compare the risk of developing primary prostate cancer between African American and Caucasian individuals. We used MP-SIR session to estimate the SIR (standardized incidence ratios) as observed/expected (O/E), and excess absolute risk (EAR) per 10,000 patients using 95% Confidence intervals (CI), with significant result when p <0.05. The latency exclusion period was set at 0 month.
Results
Among 721,385 patients included in the study with primary colorectal cancer, only 8,943 (1.24%) developed primary prostate cancer (Expected= 8,938.87, O/E= 1.00, p >0.05, 95% CI: 0.98-1.02, EAR= 0.01). Out of these cases, approximately 7,340 (82.1%) were Caucasian individuals who developed primary prostate cancer (Expected= 7,633.79, O/E= 0.96, p <0.05, 95% CI: 0.94-0.98, EAR= -1.03), while only 1,603 (17.9%) were African American individuals who developed primary prostate cancer (Expected= 1,305.08, O/E= 1.23, P <0.05, 95% CI: 1.17-1.29, EAR= 7.82). Notably, at the age of 70-74 years, Caucasian individuals exhibited a significant decrease in the risk of developing primary prostate cancer (O/E= 0.91, P <0.05, EAR= -4.12), whereas African American individuals showed a significant increase in risk at this age (O/E= 1.27, P <0.05, EAR= 14.32).
Conclusions
Our results show a higher risk of developing primary prostate cancer in African American patients compared to Caucasian patients. Further research is needed to better understand the race variations on a genetic basis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract